Sujata Arora

2.6k total citations · 1 hit paper
41 papers, 1.4k citations indexed

About

Sujata Arora is a scholar working on Surgery, Physiology and Oncology. According to data from OpenAlex, Sujata Arora has authored 41 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 12 papers in Physiology and 10 papers in Oncology. Recurrent topics in Sujata Arora's work include Nausea and vomiting management (22 papers), Anesthesia and Pain Management (11 papers) and Pathogenesis and Treatment of Hiccups (10 papers). Sujata Arora is often cited by papers focused on Nausea and vomiting management (22 papers), Anesthesia and Pain Management (11 papers) and Pathogenesis and Treatment of Hiccups (10 papers). Sujata Arora collaborates with scholars based in United States, South Africa and Canada. Sujata Arora's co-authors include Lee S. Schwartzberg, Bernardo L. Rapoport, Ian D. Schnadig, Allen Poma, Rudolph M. Navari, Manuel Modiano, Martin Chasen, Monica Mita, Bruce J. Dezube and László Urbán and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PEDIATRICS.

In The Last Decade

Sujata Arora

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 314 citations Lee S. Schwartzberg, Monica Mita et al. profile →

Peers

Countries citing papers authored by Sujata Arora

Since Specialization

Citations

This map shows the geographic impact of Sujata Arora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sujata Arora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sujata Arora more than expected).

Fields of papers citing papers by Sujata Arora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sujata Arora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sujata Arora. The network helps show where Sujata Arora may publish in the future.

Co-authorship network of co-authors of Sujata Arora

This figure shows the co-authorship network connecting the top 25 collaborators of Sujata Arora. A scholar is included among the top collaborators of Sujata Arora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sujata Arora. Sujata Arora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Smart Grid Cybersecurity: Anomaly Detection in Solar Power Systems Using Deep Learning 2025 ·Jagbir Singh, (unknown), Sujata Arora	1
2	Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis 2025 ·Clinical Pharmacology in Drug Development ·Xiaodong Wang, Minggeng Gao, Mark Matijevic, (unknown), Mason Yamashita, Sujata Arora, (unknown)	0
3	Adaptive control strategies for effective integration of solar power into smart grids using reinforcement learning 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Sujata Arora	12
4	Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers 2024 ·Advances in Therapy ·Xiaodong Wang, Richard Kirk, Mark Matijevic, Minggeng Gao, (unknown), (unknown), Sujata Arora, Tanya Fischer	1
5	Seasonal Electrical Load Forecasting Using Machine Learning Techniques and Meteorological Variables 2024 ·International Journal of Robotics and Control Systems ·(unknown), (unknown), Sujata Arora	3
6	Enhancing Hybrid Power System Performance with GWO-Tuned Fuzzy-PID Controllers: A Comparative Study 2024 ·International Journal of Robotics and Control Systems ·(unknown), Sujata Arora, (unknown)	4
7	Deep Learning Projections for High-Performance Concrete Strength Forecasting 2024 ·Rupesh Kumar Tipu, (unknown), Satvik Vats, Sujata Arora	3
8	TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. 2018 ·Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, Gini F. Fleming, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Chapman‐Davis, Gerardo Colón‐Otero, Richard T. Penson, Ursula A. Matulonis, Young B. Kim, Kathleen N. Moore, Elizabeth M. Swisher, Bruce J. Dezube, (unknown), (unknown), Sujata Arora, Pamela N. Münster	108
9	Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects 2018 ·The Journal of Clinical Pharmacology ·Xiaodong Wang, Jing Wang, Sujata Arora, (unknown), (unknown), Sharon Lu, Zhiyi Zhang	1
10	Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P‐glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers 2017 ·The Journal of Clinical Pharmacology ·Xiaodong Wang, Zhiyi Zhang, Sujata Arora, (unknown), Jing Wang, Daniel Powers, (unknown), Sharon Lu, Vikram Kansra	14
11	Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study 2017 ·The Journal of Clinical Pharmacology ·Xiaodong Wang, Zhiyi Zhang, Daniel Powers, Jing Wang, Sharon Lu, Sujata Arora, (unknown), (unknown), Vikram Kansra	16
12	Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy 2016 ·Supportive Care in Cancer ·Martin Chasen, László Urbán, Ian D. Schnadig, Bernardo L. Rapoport, (unknown), Sujata Arora, Rudolph M. Navari, Lee S. Schwartzberg, Cesare Gridelli	10
13	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy 2016 ·European Journal of Cancer ·Bernardo L. Rapoport, Lee S. Schwartzberg, Martin Chasen, (unknown), Sujata Arora, Rudolph M. Navari, Ian D. Schnadig	25
14	Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. 2016 ·Journal of Clinical Oncology ·Bernardo L. Rapoport, Lee S. Schwartzberg, Sujata Arora, Daniel Powers, Karin Jordan, Rudolph M. Navari	2
15	Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC) 2015 ·Supportive Care in Cancer ·Bernardo L. Rapoport, Daniel T. T. Chua, Allen Poma, Sujata Arora, Yan Wang, Luis Fein	51
16	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial 2015 ·The Lancet Oncology ·Lee S. Schwartzberg, Manuel Modiano, Bernardo L. Rapoport, Martin Chasen, Cesare Gridelli, László Urbán, Allen Poma, Sujata Arora, Rudolph M. Navari, Ian D. Schnadig	119
17	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy. 2015 ·Journal of Clinical Oncology ·Daniel Powers, Ian D. Schnadig, Manuel Modiano, Sujata Arora, Lee S. Schwartzberg	2
18	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials 2015 ·The Lancet Oncology ·Bernardo L. Rapoport, Martin Chasen, Cesare Gridelli, László Urbán, Manuel Modiano, Ian D. Schnadig, Allen Poma, Sujata Arora, Vikram Kansra, Lee S. Schwartzberg, Rudolph M. Navari	105
19	The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β‐Carotene in Healthy Volunteers 1996 ·The Journal of Clinical Pharmacology ·Jianguo Zhi, Angela T. Melia, (unknown), Sujata Arora, Indravadan H. Patel	49
20	The Influence of Reduced Dietary Fat Absorption Induced by Orlistat on the Pharmacokinetics of Digoxin in Healthy Volunteers 1995 ·The Journal of Clinical Pharmacology ·Angela T. Melia, Jianguo Zhi, (unknown), Bo H. Min, (unknown), (unknown), Sujata Arora, Sharon Passe	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact